Patients with aHUS are at ongoing risk of systemic, life-threatening, and sudden complications1-4
aHUS patients can show involvement in more than one organ system5-8,*
Click the round targets below, for the aHUS effects on the organ system.


-
Close
Up to 49% of patients experience neurological symptoms, including6
- Confusion6
- Stroke5
- Encephalopathy5,7
- Seizure6
-
Close
Up to 44% experience cardiovasculuar symptoms, including6
- Myocardial infarction5,7
- Hypertension6
- Arterial thrombosis5
- Vascular stenosis7
- Cardiomyopathy6
-
Close
Up to 34% of patients experience thrombi outside of the kidney9
-
Close
Up to 51% experience GI symptoms, including6
- Colitis5
- Gastroenteritis3
- Abdominal pain6
- Pancreatitis5
- Diarrhea6
- Nausea/Vomiting5
-
Close
More than 50% of patients progress to end-stage renal disease4,6
- Elevated creatine6
- Decreased estimated glomerular filtration rate (eGFR)1
- Proteinuria8
-
Close
Up to 46% experience pulmonary symptoms, including9
- Dyspnea10
- Pulmonary edema10
- Pulmonary hemorrhage11
In one study, 42% (8/19) of patients progressed to end-stage renal disease or death without overt signs and symptoms of TMA4
In aHUS, excessive complement activation leads to systematic TMA, progressive worsening of vital organ function, and multiorgan failure13-16
1. Legendre CM, et al. N Engl J Med. 2013;368(23):2169-2181. 2. Azoulay E, et al. Chest. 2017;152(2):424-434. 3. Goodship THJ, et al. Kidney Int. 2017;91(3):539-551. 4. Fremeaux-Bacchi V, et al. Clin J Am Soc Nephrol. 2013;8(4):554-562. 5. Campistol JM, et al. Nefrologia. 2015;35(5):421-447. 6. Jamme M, et al. PLoS One. 2017;12(5):e0177894. 7. Hofer J, et al. Front Pediatr. 2014;2:1-16. 8. Krishnappa V, et al. Ther Apher Dial. 2018;22(2):178-188. 9. Muus P, Loirat C, Licht C, et al. Presented at: 18th Congress of the European Hematology Association. June 13-16, 2013; Stockholm, Sweden. Abstract B1774. 10. Sallee M, et al. Nephrol Dial Transplant. 2010;25(6):2028-2032. 11. Sellier-Leclerc A-L, et al. J Am Soc Nephrol. 2007;18(8):2392-2400. 12. Noris M, et al. Nat Rev Nephrol. 2014;10(3):174-180. 13. Laurence J, et al. Clin Adv Hematol Oncol. 2016;14 Suppl 11(11):2-15. 14. Noris M, et al. Clin J Am Soc Nephrol. 2010;5(10):1844-1859. 15. Caprioli J, et al. Blood. 2006;108(4):1267-1279. 16. Langman C. Haematologica. 2012;97(s1):195-196.